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Abstract 
 
Comparison of trough levels of two vancomycin formulations in a selected 
preterm infant population 
 
 
Heletje Aletta Griesel 
 
M.Pharm thesis, School of Pharmacy, University of Western Cape. 
 
 
 
Infections contribute 26% of the 4 million neonatal deaths occurring annually in 
developing countries. 
Late onset nosocomial sepsis is often caused by gram positive bacteria including 
Stapylococcus aureas, Stapylococcus epidermidis; coagulase-negative staphylococci 
(CONS), Enterococcus species and methicillin resistant Staphylococcus aureas 
(MRSA). 
The antibiotic of first choice for MRSA is vancomycin, a glycopeptide with bactericidal 
activity against gram-positive bacteria. 
There are limited studies in premature infants on the equivalence of generic 
formulations of vancomycin. 
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The aim of this study was to compare the trough plasma levels of Aspen-Vancomycin® 
(AV); and Sandoz-Vancocin CP® (SV) in premature infants with suspected Methicillin 
Resistant Staphylococcus aureus (MRSA) infection. 
The study was designed as a prospective, double blind, randomised trial involving male 
and female premature infants admitted in the Neonatal Intensive care Unit (NICU) at 
Netcare Blaauwberg and N1-city Hospitals for treatment of suspected MRSA-infection 
between April 2012 and June 2013. 
The inclusion criteria were: 29-35 weeks postmenstrual age (PMA), informed and 
written consent from parents of each premature infant enrolled in the study. 
 
Blood samples (0.3-0.4ml) were collected for renal function test and vancomycin trough 
levels determination.  
Blood samples for vancomycin trough level assay were collected thirty minutes prior to 
the administration of the third dose of vancomycin. 
Statistical analysis was performed and estimation was made giving an indication of how 
many infants will be needed to make the study statistically significant.  
Wilcoxon Two-Sample test was performed to determine the p-values and Spearman 
correlation coefficients were used to determine the correlation between trough levels 
and variables. P-values < 0.05 were considered significant. 
 
A total of 19 premature infants met with study criteria, 10 (5 females and 5 males) 
received AV and 9 (6 females and 3 males) receive d SV.   
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There was no statistical significant difference between the demographic (GA, BW, PMA, 
PNA, weight at trial entry, height at trial entry) and biological (albumin, serum creatinine 
concentration and glomerular filtration rate) parameters of the premature infants in the 
AV and SV group. 
There were no statistical significant difference between trough level 1 of AV and SV, 
although trough level 1 had a lower trend in the SV group (p=0.118). 
No AV trough level 1 was below the minimum effective concentration (<5µg/ml).  It was 
found that 30% of AV trough level 1 was within the therapeutic range (5-10µg/ml) and 
70% of AV trough level 1, were above minimum toxic concentration (>10mg/l).  
 It was found that 22.2% of SV trough level 1 was below minimum effective 
concentration, 44.4% of SV trough level 1 was within therapeutic range and 33.3% of 
trough level 1 was above minimum toxic concentration.  
No correlation was found between trough level 1 and the demographic and biological 
parameters of the premature infants in the AV group.  SV had a positive correlation with 
GA, BBW, PMA and a negative correlation with PNA. 
 
Vancomycin serum trough concentrations are dependent on demographic, biological 
and pharmacokinetic parameters. Since the first two parameters was of no definitive 
value one needs to investigate the effect of pharmacokinetic parameters on serum 
vancomycin trough levels. 
It was found that a premature infant’s renal function drives vancomycin trough level 
concentrations and that age or weight are the most relevant covariates of vancomycin 
 
 
 
 
v 
 
clearance and should be considered in individual vancomycin dosing schedule in 
premature infants by means of therapeutic drug monitoring.   
This study suggests that Sandoz Vancocin CP® should be used when treating 
premature infants for a suspected MRSA infection. Sandoz Vancocin CP® offered lower 
vancomycin serum trough levels which ensure a lower risk of toxicity. 
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The time for war and the time for peace. 
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Neonatal age terminology 
 
The following terminologies will be used to describe the age of the premature infant: 
 
Gestational age: 
The gestational age (GA) is the age from the first day of the last menstrual period until 
the day of delivery, measured in weeks (Engle, 2004). The gestational age can be 
calculated by using an ultrasound, measuring the first day of the last menstrual period 
(LMP), and physical examination of the infant according to the new Ballard score 
(Fenton & Kim, 2013). 
 
Post natal age (PNA): 
It is the time from birth measured in days, weeks, months and years (Engle, 2004). 
 
Post menstrual age (PMA): 
The age of the infant from the first day of the last menstrual cycle plus the time elapsed 
from birth (post natal age), measured in weeks (Engle, 2004). 
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Corrected age: 
The corrected age is the post natal age minus the amount of weeks before 40 weeks 
gestation, measured in weeks and months (Engle, 2004). 
 
Figure 2.1: Age terminology during the perinatal period (Engle (2004) 
 
 
 
 
 
 
 
 
 
 
Low birth weight premature infants (LBW): 
A premature infant is defined as LBW if her/his birth weight is < than 2500g at birth 
(Beers et al, 2006). 
 
Very low birth premature infant (VLBW): 
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A premature infant is defined as LBW if her/his birth weight is < than 1500g at birth 
(Beers et al, 2006). 
 
Small for gestational age (SGA): 
Premature infants whose weight is less than the 10th percentile for gestational age 
(Beers et al, 2006). 
 
 
Intra-uterine growth retardation (IUGR): 
Intra-uterine growth retardation refers to poor growth of a baby while in the mother's 
womb during pregnancy (Beers et al, 2006). 
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1.1 Background information 
Increased mortality and morbidity in neonatal intensive care units (NICUs) is a concern, 
especially in the developing countries in the world according to Satar & Ozlu (2012). 
Lawn et al (2005) note that 95% of neonatal deaths arise from low- and middle-income 
countries, such as south-central Asia and sub-Saharan Africa. 
According to Qazi & Stoll (2009) and Lawn et al (2005), there are three major causes 
which contribute to neonatal deaths: infection (36%), consequences of premature 
birth/low birth weight (28%) and birth asphyxia (23%). 
Satar & Ozlu (2012) found that the occurrence of neonatal sepsis in developed 
countries varies from one to five cases per 1000 live births, while in developing 
countries some reports state clinical sepsis rates to range from 49 to 170 cases per 
1000 live births.  
It is a challenge to identify and treat of neonatal sepsis, particularly in developing 
countries. If the correct antibiotic is not prescribed within an hour of suspected sepsis it 
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might lead to a prolonged neonatal inflammatory response and undesired 
neurodevelopment (Qazi & Stoll, 2009, Sherman, 2010). 
Late onset nosocomial sepsis is often caused by gram positive bacteria and the 
Staphylococcus species account for 30 to 50% of all infections (Satar & Ozlu, 2012). 
Rana et al (2012) found that during the period that they conducted their study the 
incidence of Methicillin resistant Staphylococcus aureus (MRSA) cultures increased 
from 13.7- 24.77 per 1000 admissions (p=0.01). Kayange et al (2010) found in their 
study in Sub-Saharan Africa that 28% of Staphylococcus aureus positive cultures were 
MRSA. 
MRSA infections can be treated with linezolide, teicoplanin and vancomycin. That is the 
opinion of Beers (2006). The first choice antibiotic, however, is vancomycin. 
Tattevin et al (2013) mentioned that Elli Lilly, the originator of vancomycin, discontinued 
the manufacturing of vancomycin towards the end of 2004. Nambiar et al (2012) note 
that since then generic vancomycin products have emerged in the market and are being 
used all over the world. With the introduction of these generic formulations into the 
market, multiple cases of impurities and sub-optimal antimicrobial activity have been 
reported such as β-lactam agents, antifungal agents and glycopeptides e.g. 
vancomycin. Snyman et al (2009) refer in their study that there is criticism around the 
world regarding the bioequivalence of generic products.  
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1.2 Motivation for this study 
In South Africa sepsis and pneumonia account for 36% of neonatal deaths, according to 
Jeena et al (2008). This makes it critical that the antibiotic therapy of choice is effective 
against the bacterial pathogens and that toxicity is avoided at all costs. This opinion is 
shared by Pritchard et al (2010) and Kayange et al (2010). 
The efficacy of vancomycin has been questioned since the emergence of vancomycin 
resistance in isolates of Staphylococcus aureus (Howden, 2010).  
 
Various studies have been performed in adults in order to determine the efficacy of 
generic formulations of vancomycin, but no study has been done in the premature infant 
population. This is found by Vesga et al (2010). On a broader level it becomes 
necessary to test the assumption that generic formulations are not only 
pharmaceutically equivalent, but also therapeutic equivalent to the innovator (Tattevin et 
al, 2013). 
It is against this background that this study seeks to investigate whether there is a 
difference between two generic formulations of vancomycin which are available in South 
Africa, with regards to trough levels measured in a selected premature infant population. 
   
 
 
 
 
Chapter 1: Introduction 
 
4 
 
Aim of this study 
The aim of the study is to compare vancomycin serum trough levels (Cmin) of the two 
vancomycin preparations available in South Africa: (a) Aspen-Vancomycin®; 
vancomycin 500mg vial (Aspen Pharmaceuticals) and (b) Sandoz-Vancocin CP; 
vancomycin 500mg vials (Sandoz Pharmaceuticals) in a selected premature infant 
population presenting with suspected MRSA infection. 
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2. Neonatal sepsis 
 
2.1 A global perspective 
The increase of neonatal morbidity and mortality, especially in developing countries are 
of great concern. Almost 99% of the four million neonatal deaths annually occur in 
developing countries (Thaver& Zaidi , 2009). The highest number of neonatal deaths is 
in low-and middle-income countries such as south-central Asia and sub-Saharan Africa 
(Lawn et al, 2005). 
There are three major causes that contribute to neonatal deaths: infection (36%), birth 
asphyxia (23%) and consequences of premature birth/low birth weight (28%) (Qazi & 
Stoll, 2009) (Lawn et al, 2005). 
Neonatal infections are contributing to the global burden of child mortality. The mortality 
rate of neonatal infections is as high as 40-50 per 1000 live births in the poorest parts of 
the world. The main reason for such high neonatal infection rates can be attributed to 
Chapter 2 Literature 
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the poor hygiene during labour and delivery and lack of resources for good postnatal 
care (Zaidi et al, 2005). 
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2.2 The incidence of neonatal sepsis in developing countries 
Sepsis is defined as a syndrome with systemic signs of infection accompanied by 
bacteraemia (Satar & Ozlu, 2012). The incidence of sepsis in developing countries 
varies from 49-170 per 1000 live births, whereas in developed countries 1-5 cases are 
reported  per 1000 live births (Satar & Ozlu, 2012). In South Africa sepsis and 
pneumonia account for 36% of neonatal deaths (Jeena et al, 2008).   
 
The identification of neonatal sepsis and the treatment thereof is challenging, 
particularly in developing countries. Some of the challenges are: lack of recognition of 
the subtle symptoms of sepsis; infants are brought late to the health care facility by the 
family; lack of access to qualified and trained health care workers, lack of quality health 
care facilities as well as the prohibitive cost of medical treatment in resource-poor 
countries (WHO, 2011). 
 
2.3 Consequences of neonatal sepsis 
 
Neonatal sepsis results in significant morbidity and mortality in premature infants in 
neonatal intensive care units (NICUs) (Cooke et al, 1997). The mortality rate of neonatal 
sepsis where premature infants have not been treated adequately is as high as 50%. 
Neonatal sepsis is a major cause of neonatal deaths in the first month of life, attributing 
13-15% (Kermorvant-Duchemin et al, 2008). 
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In a large cohort study, Stoll et al (2004) note that premature infants that had survived 
neonatal sepsis in comparison to those who had not been infected, were more likely to 
develop cerebral palsy (p≤0.01), had lower mental developmental index (MDI) scores 
(p≤0.01), lower psychomotor development index (PDI) scores (p≤0.001) and suffered 
from visual (p≤0.001) and growth impairment (p≤0.001).   
 
If the correct antibiotic is not prescribed within an hour of suspected sepsis it may lead 
to a prolonged neonatal inflammatory response and undesired neurodevelopment as 
described by (Qazi & Stoll, 2009) (Sherman, 2010). 
 
2.4 Neonatal sepsis: Early-onset sepsis and late-onset sepsis 
 
Neonatal sepsis can be divided into two groups according to the postnatal age of the 
infant: Early-onset sepsis (EOS) that occurs within 48 hours to 6 days of birth; and late-
onset sepsis (LOS) occurring 6 days after birth (Satar & Ozlu, 2012). 
Klebsiella spp. accounted for 28.2% and Staphylococcus aureus 14.3% of all isolated 
obtained from blood cultures in Africa. Methicillin Resistant Staphylococcus aureus 
(MRSA) contributes to 25% of LOS in Africa and 38% in all developing countries (Zaidi 
et al, 2009).  
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2.5 Risk factors for neonatal sepsis 
2.5.1 The premature infant’s immune system 
Neonatal immune systems are immature and more susceptible to infection (gram 
positive- and negative bacteria and fungi) (Soltau & Schelonka, 2008).  
Premature infants have a poorly developed skin barrier and decreased development of 
pro-inflammatory cytokines e.g. interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and 
interferon-γ and therefore their immune system is compromised (Satar & Ozlu, 2012).  
Further risk factors can be divided into intrinsic, extrinsic, and risk factors related to 
institutional infrastructure. 
2.5.2 Intrinsic risk factors 
The intrinsic risk factors can be described as factors that cannot be influenced and it 
relates to the premature infant’s biological status. The factors include birth weight, 
gestational age and conditions at birth (Downey et al, 2010). 
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2.5.3 Extrinsic risk factors 
Extrinsic factors relates to the treatment the premature infant receives including 
mechanical ventilation, central venous devices and parenteral nutrition (TPN) (Downey 
et al, 2010). 
2.5.4 Infrastructure related risk factors 
Lastly, infrastructure-related risk factors include environmental cleanliness, hand 
washing, isolation facilities and nursing staff (Downey et al, 2010). 
2.6 Clinical signs and symptoms of neonatal sepsis 
Symptoms of neonatal sepsis are often minor and include lethargy, apnoea, hypotonia 
and feeding intolerance (Cooke et al, 1997). Clinical signs include hypotension, glucose 
dysregulation, an elevated white cell count (WCC), thrombocytopenia and an increase 
in infection markers e.g. C-reactive protein (CRP) and procalcitonin (PCT) (Ghazal et al, 
2013). Because the symptoms could easily go unrecognised, it is crucial that neonatal 
sepsis is diagnosed as early as possible. 
2.7 Diagnosis of neonatal sepsis 
Untreated sepsis can account for more than 50% mortality rate. Physicians find it too 
great a risk to wait for positive cultures to confirm sepsis, therefore they will initiate 
therapy while waiting for culture results (Kermorvant-Duchemin et al, 2008). Late-onset 
neonatal sepsis is best diagnosed with a positive blood culture. Blood, urine and 
cerebrospinal fluid (CSF) should be collected if sepsis is suspected, before commencing 
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antimicrobial treatment (Satar & Ozlu, 2012). Various biomarkers are available to aid in 
the diagnosis of sepsis (Chiesa et al, 2011) as discussed below. 
 
2.7.1 Clinical biomarkers 
2.7.1.1 C-reactive protein (CRP) 
CRP, the most widely used diagnostic infection biomarker, is synthesised by the liver 
after six hours of onset of inflammation and tissue necrosis and peaks at 36-50 hours. It 
is also used in neonates to diagnose bacterial sepsis (Nabulsi et al, 2012 and Chiesa et 
al 2011). Mahbuba Meem et al (2011) found that the cut-off point for a positive CRP 
was 17mg/L with 66% sensitivity and 86% specificity. 
 
2.7.1.2 Procalcitonin (PCT) 
PCT is a precursor peptide from the hormone calcitonin (Satar & Ozlu, 2012 and 
Vazzalwar et al, 2005). Serum PCT concentrations increase in systemic inflammation 
particularly when the inflammation is caused by bacterial infection (Vazzalwar et al, 
2005). When compared with CRP, PCT has a higher sensitivity in identifying late-onset 
sepsis in VLBW premature infants (Vazzalwar, 2005). According to Auriti et al (2012) a 
serum PCT value of > 2.4ng/ml in VLBW premature infants increase the accuracy for 
neonatal sepsis before a blood culture confirms neonatal sepsis. 
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2.7.1.3 Complete blood count (CBC) 
A complete blood count (CBC) is a rapid, inexpensive and readily available diagnostic 
test to determine late onset neonatal sepsis CBC results include a white blood cell 
(WBC) count, absolute neutrophil count (ANC), immature-to-total neutrophil count (I/T 
ratio), and platelet counts. Hornik et al (2012) found that a WBC count < 1000cells/mm3 
or > 50 000cells/mm3 and a platelet count of < 50 000cells/mm3 were associated with 
late-onset sepsis. (Hornik et al, 2012). 
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2.8 Gram positive neonatal sepsis 
Late onset nosocomial sepsis is often caused by gram positive bacteria including 
Staphylococcus aureus, Staphylococcus epidermidis; coagulase-negative staphylococci 
(CONS); Enterococcus species and methicillin resistant Staphylococcus aureus (MRSA) 
(Ghazal, 2013). 
Staphylococci infection account for 30-50% of late-onset infections and can be 
attributed to intravascular devices e.g. umbilical artery, intravascular catheters (Satar & 
Ozlu, 2012) as well as endo-tracheal intubation and other invasive lines (Anderson, 
2006) (Behrman, 2000). 
2.9 Methicillin-resistant Staphylococcus aureus (MRSA) 
MRSA is a well known nosocomial pathogen that is responsible for serious bacterial 
infections in premature infants and outbreaks in NICUs (Maraqa, 2011). MRSA 
developed resistance to βeta-lactam antibiotics such as cephalosporins and penicillins 
(oxacillin, nafacillin and cloxacillin) (Haddadin, 2002). 
The major route of transmission is from one premature infant to another by means of 
contact via healthcare workers (Maraqa, 2011). Active surveillance by means of routine 
MRSA screening, isolation of premature infants and rigorous attention to environmental 
decontamination and hand wash has proven to reduce the incidence of MRSA 
infections in NICUs (Maraqa, 2011). 
Rana et al (2012) found that during their study period the incidence of MRSA cultures 
increased from 13.7- 24.77 per 1000 admissions (p=0.01). A sub-Saharan Africa study 
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found that 28% of their Staphylococcus aureus positive cultures were MRSA (Kayange 
et al, 2010). 
Maraqa et al (2011) stated that risk factors contributing to MRSA infection include 
delivery by Cesarean section, low birth weight, multiple gestation and longer length-of-
stay in the NICU. The factors that predicts a positive blood culture are cyanosis, 
lethargy, premature rupture of membrane (PROM), meconium stained liquor and 
convulsions (Kayange, 2010). 
Treatment of suspected MRSA  
MRSA infections can be treated with gram positive antibiotics such as linezolide, 
teicoplanin and vancomycin (Beers, 2006). The first choice antibiotic is vancomycin 
(Lutsar & Metsvaht, 2010). 
 
2.10 Vancomycin 
 
Vancomycin is a glycopeptide antibiotic with bactericidal activity against gram-positive 
bacteria (Hardman et al, 2001). It was originally produced by an Actinomycete isolated 
from soil samples obtained in Indonesia and India, called Streptococcus orientalis 
(Hardman et al, 2001). Vancomycin is a fermentation product and to produce the active 
pharmaceutical ingredient (API) at industrial level requires complex processes for 
biosynthesis and purification (Tattevin et al, 2013).  Since Eli Lilly has stopped the 
production of the originator, Vancocin CP, the market has seen an increased in generic 
vancomycin formulations, all with debatable efficacy. (Vesga et al, 2010). 
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2.10.1 Mechanism of action of vancomycin 
The bactericidal activity of vancomycin is based on the inhibition of bacterial cell wall 
synthesis through hydrogen bonding to the C-terminal D-Ala-D-Ala residue portion of 
peptidoglycan precursor. It forms a non-covalent complex, which inhibits the precursor 
for cell wall synthesis (Howden, 2010). Any process that interferes with vancomycin 
binding to the D-Ala-D-Ala residue decreases the binding potency of the drug (Howden, 
2010). 
2.10.2 Side effects of vancomycin 
According to Hardman (2001), one of the most common side effects of vancomycin 
administration is the so-called “Redman syndrome”. It is associated with erythematous 
or urticarial reactions, flushing, tachycardia and hypotension. This phenomenon is 
caused by the rapid infusion of vancomycin. Therefore vancomycin should be infused 
over a period of at least 60 minutes to avoid the symptoms associated with “Redman 
syndrome”. Hypersensitivity reactions, including skin rashes may occur in 5% of 
patients. Reversible neutopenia and eosinophilia have been reported (Gibbon, 2005). 
2.10.3 Toxicity 
Auditory impairment is associated with high concentrations of vancomycin in plasma. It 
is seldom permanent and is worsened when co-administered with other ototoxic drugs 
e.g. aminoglycocides (Hardman, 2001).  
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Nephrotoxicity is defined as an increase of ≥50% in serum creatinine levels from 
baseline during vancomycin therapy (Pritchard et al, 2010). Nephrotoxicity has become 
an unusual side effect in premature infants when administered at appropriate doses. 
Caution must be exercised when administered with other nephrotoxicity drugs e.g. 
amikacin and gentamycin (Hardman, 2001). 
 
2.11 Pharmacokinetic parameters of vancomycin 
 
Pharmacokinetics is the science of the kinetics of drug absorption, distribution, 
elimination (excretion) and metabolism. Age, genetic, gender and ethnic differences 
may also contribute to pharmacokinetic differences in the general population (Shargel, 
2005). 
 
The following pharmacokinetic parameters are of value: peak plasma concentrations 
(Cmax), trough concentrations (Cmin), the apparent volume of distribution (Vd), renal 
clearance (Cl), elimitation half life (t1/2), metabolism, protein binding and the area under 
the curve (AUC) (Shargel et al, 2005). 
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2.11.1 Peak plasma concentration (Cmax) 
The peak plasma concentration can be defined as the concentration achieved after a 
single dose. The measured plasma peak concentration should be between 30-40mg/L 
(Horn, 2007, De Hoog et al, 2000 and Rodvold et al, 1995). 
 
2.11.2 Trough plasma concentration (Cmin) 
The trough level presents the minimum amount of the drug present in the blood. 
(Ulldemolins et al, 2011). The desired trough concentration for vancomycin is 5-10mg/L 
(McDougal et al, 1995, Rodvold et al, 1995 and Marsot et al, 2012). In meningitis the 
trough level should reach 10-15mg/L (Horn et al, 2007). There is conflicting evidence in 
the literature regarding the timing of trough levels. Some studies suggest (1) half an 
hour before the third dose (De Hoog et al, 2000), (2) half an hour before the fourth dose 
(Rybak et al, 2009). 
There seem to be various recommendations in literature with regards to the dosing of 
vancomycin in premature infants. In a study done by Koren & James (1987), it was 
found that if the dosing of vancomycin is based on the PMA, 75.5% of the trough 
concentrations taken were within therapeutic range of < 10mg/l.  
McDougal et al (1995) did a study where it was found that for premature infants with a 
PMA of 31-36 weeks, a vancomycin dosing schedule of 18mg/kg eighteen hourly and 
trough levels collected 30min before the third dose the mean trough levels were 3.4 ± 
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0.6mg/l. No bacteriologic treatment failures were reported during this study despite the 
low though levels obtained.  
In another study done by Machado et al (2007) the premature infants were divided into 
two groups with a statistical difference in PMA and PNA. All infants were dosed 
according to standard guidelines. It was found that group 1 with a statistically lower PNA 
(p=0.02) and PMA (p<0.001) had lower trough levels than group 2. It can be attributed 
to the increased extracellular fluid in group 1. It was also found that the Vd differed 
significantly between the two study groups (p=0.01) and that the volume of distribution 
can be inversely correlated to the PNA and PMA of premature infants (Machado et al, 
2007).    
 
2.11.3 Volume of distribution (Vd) 
The volume of distribution can by defined as the theoretical volume of fluid into which 
the total drug that was administered would be diluted, to produce a drug concentration 
in the plasma (Beers et al, 2006). Hydrophylic drugs, e.g. vancomycin, predominantly 
distribute into intravascular and interstitial fluid. These drugs do not penetrate the 
intracellular space in meaningful concentrations, due to the fact that it is unable to 
passively cross the lipid cellular membrane (Ulldemolins et al, 2011). 
In premature infants the volume of distribution of hydrophyllic drugs is affected by the 
total body water and the extracellular fluid volume (Ulldemolins et al, 2011 and Marsot 
et al, 2012). According to one study the volume of distribution for a neonatal study 
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population (PMA = 34.6weeks; weight=1700g) was 0.572L/kg-1 (Marqués-Minana et al, 
2010).   
Vd in premature infants differ from that of adults and young children (Marqués-Minana 
et al, 2010) (Noya, 1998). The Vd in premature infants is larger than in adults (Marqués-
Minana, 2010 and De Hoog et al, 2004). In premature infants (<2kg) approximately 80% 
of their body composition is extracellular fluids and water (Noya et al, 1998). Premature 
infants’ extracellular body fluid decreases postnatally with a resultant in a decrease in 
vancomycin's Vd, resulting in higher trough levels than anticipated (Marqués-Minana et 
al, 2010). It was also found that a premature infant’s current body weight has a strong 
positive correlation to the volume of distribution (Rocha et al, 2006). This finding were 
also supported by McDougal et al (1995) where it was found that the absolute Vd 
correlates with PMA (p<0.0001), but when compared with normalised Vd there was no 
correlation with PMA (p=0.59). This suggests that with an increased PMA, the absolute 
Vd decreases and that it is a function of body weight and not maturation of other 
physiological systems (McDougal et al, 1995). 
2.11.4 Metabolism 
 
Vancomycin is degraded into CDP-1 (a biological inactive degradation product 
(Vollmerhaus et al, 2003) when exposed to heat over time. Theoretically the 
accumulation of CDP-1 could be responsible for therapeutic failure (due to under dosing 
of vancomycin) and drug induced toxicity (Somerville et al, 1999). 
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2.11.5 Elimination 
Vancomycin is eliminated 80-90% unchanged by the kidneys (Gibbon et al, 2005). A 
small amount of vancomycin is eliminated via non-renal mechanisms of unknown origin 
(Marsot et al, 2012). 
2.11.6 Vancomycin clearance (CL) 
Vancomycin clearance (CL) is defined as the quantification of irreversible loss of drug 
form from the body’s metabolism and excretion mechanisms (Ulldemolins et al, 2011). 
Given vancomycin’s route of elimination via the kidneys, it is logical to assume that 
there is an association between the glomerular filtration rate (GFR) and the drug’s 
clearance. The correlation between serum creatinine and the GFR with vancomycin 
clearance has been discussed in various studies according to the review article done by 
De Hoog et al (2004). Furthermore James et al (1987) found a positive linear correlation 
between the PMA of the premature infant and vancomycin clearance. This finding was 
supported by a study done by Reed et al (1987). It was also found in the same study 
done by Reed et al that the premature infant’s body weight had a strong positive 
correlation with vancomycin clearance. This finding was also supported by Rocha et al 
(2006) where it was found that the premature infant’s body weight at trial entry had a 
strong positive correlation with vancomycin clearance.   
 
According to McDougal et al. (1995) the mean absolute clearance (L/h) of vancomycin 
increases with an increase in PMA (p<0.0001). When the PMA is compared with 
normalised clearance (L/kg/h) there still exists a correlation between PMA and 
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normalised clearance (p<0.005) (McDougal et al, 1995). This suggested that the 
increase of absolute clearance with an increased PMA was not due to body weight 
alone, but also due to maturation of the renal function (McDougal et al, 1995). Thus the 
variables that have a strong influence on vancomycin clearance are the premature 
infant’s body weight at trial entry, the PMA and the serum creatinine concentration. 
 
2.11.6.1 Serum creatinine concentration a marker of renal function 
 
Serum creatinine concentrations are widely used to describe the renal function of 
premature infants. Serum levels of > 130µmol/l is considered to be an indicator of renal 
impairment.   
 
James et al (1987) did a study where it was found that serum creatinine concentration 
had a positive correlation with the half life of vancomycin and that the serum creatinine 
concentration had an irreversible correlation with vancomycin clearance. This finding 
was supported by Grimsley & Thomson (1999). They also found that if vancomycin 
were dosed according to serum creatinine concentrations, 75% of the trough levels 
were within the desired range of 5-12µg/ml. Thayyil et al (2008) reported that serum 
creatinine levels are influenced by gestational age (GA) and the post natal age. 
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2.11.6.2 Glomerular filtration rate (GFR) of premature infants  
Vancomycin is excreted primarily through the kidneys by means of glomerular filtration 
(Marqués-Minana et al, 2010). 
Renal mechanisms are physiologically immature in newborn infants and the glomerular 
filtration rate (GFR) is 25% of that of adults and even lower in very premature infants 
(Noya, 1998)  
Nephrogenesis starts at 5-6 weeks of gestation and is only fully completed at 36 weeks 
of age (De Cock et al, 2012 and Schreuder et al, 2009). Infants that were born 
prematurely (before the completion of nephrogenesis) have been shown to have less 
nephrons (Schreuder et al, 2009). 
 
It was found that the measurement of GFR is unreliable in premature infants, because it 
reflects that of maternal serum creatinine concentrions. Grimsley & Thompson (1999) 
reported that the pharmacokinetics of vancomycin, including clearance, depended on 
both the current weight of the infant, as well as the serum creatinine levels. 
The GFR in premature infants can be calculating using the following equation: 
GFR = 0.33 x height (cm)/ Serum creatinine concentration (µmol/l). The GFR is 
expressed as ml/min/1.73m2. Normal values for premature infants 30-32 weeks is 0.3-
1.3 ml/min/1.73m2 and for premature infants 33-35 weeks is 0.5-1.5 ml/min/1.73m2. 
(Brion et al, 1986). 
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2.11.7 Vancomycin half life (t½) 
The half life (t½) can be defined as the time required for the plasma concentration of a 
drug to be eliminated by 50% (Ulldemolins et al, 2011). The t½ of vancomycin is 
approximately 4-8 hours in adults with normal renal function (Hardman, 2001 and De 
Hoog et al, 2004). In a study done by McDougal et al it was reported that the t½ in 
premature infants was 5.59 ±0.36 hours for premature infants with a PMA of 31-36 
weeks. The t½ of most drugs, especially hydrophilic drugs, is longer in premature 
infants, due to their increased percentage of body water (De Hoog et al, 2000). In 
various studies it was found that the t½ of vancomycin in premature infants is between 
3.5-10 hours. (De Hoog et al, 2004). James et al (1987) found that the t½ of 
vancomycin has a negative correlation with PMA (p<0.0001) and a positive linear 
correlation with serum creatinine concentrations (p<0.0001). 
2.11.8 Steady state 
Steady state is observed when the elimination rate of a drug equals the administration 
rate. Steady state is approximately five times the drug’s t½ (Shargel et al, 2005).  
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2.11.9 Protein binding 
Protein binding refers to the proportion of the drug that binds to plasma proteins 
(Ulldemolins et al, 2011). 
 
Vancomycin is 50-55% plasma protein bound, mainly to albumin and Immunoglobulin A 
(IgA) (Rybak et al 2009 and Sun et al 1993) and not to α-1 acid glycoprotein. While 
albumin is synthesised in the liver, its concentration is often low in premature infants in 
the first few weeks of life (Sun et al, 1993). Reduced plasma protein binding e.g. 
albumin bounding is associated with differences in body compartments (extracellular 
fluid) and frequently influence the volume of distribution (Jackson et al, 1999). 
 
 
 
 
 
 
Chapter 2: Literature review 
 
25 
 
 Table 2.1: Results of pharmacokinetic studies in premature infants (Pacifici & Allegaert, 
2012) 
Reference Reed et al 
(1987) 
McDougal et 
al (1995) 
(Group 2) 
De Hoog et al 
(2000) 
Retrospective 
study 
Asbury et al 
(1993) 
Sample size (n) 15 15 108 19 
Gestational age 
(weeks) 28.4 ± 2.6 29.4 ± 28.9a 29.3 ± 4.2 
Post natal age 
(days) 20.5 ± 10.4 23 ± 14 14b 33.9 ± 19.9 
Postmenstrual age 
(weeks) 31.4 32.9 N/Ac 34.2 
Weight (g) 1069 ± 435 1194 ± 412 1045 1780 ± 1080 
Dose (mg/kg) 12.6 Q24h 18 Q18h 15 Q12h note A 
Clearance (CL) (L/h) 1.22 ± 0.7 1.19 ± 0.08 3.4 ± 0.11 1.22 ± 0.54 
Volume of 
distribution (Vd) L/kg 0.53 ± 0.13 0.56 ± 0.02 0.43 ± 0.013 0.52 ± 0.08 
Half life (t1/2) 6 ± 2.0 5.6 ± 0.36 6 ± 0.27 5.6 ± 1.2 
Peak levels (µg/ml) 31.2± 12 27.9 ± 1.2 34.3 ± 7.7 27.8 ± 0.7 
Trough level (µg/ml) 9.5 ± 3.5 3.9 ± 0.6 8.2 ± 2.2 7.5 ± 1.2 
a
mean; 
b
median;
c
 NA: Not available 
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2.12 Pharmacodynamics of vancomycin 
Pharmacodynamics (Pd) refers to the study of the relationship between the drug 
concentration in the human body and the effect it exhibits. The 
pharmacokinetic/pharmacodynamic characteristics of a particular drug seek to establish 
a relationship between the dosage of a drug and its pharmacological effect in the 
human body (Ulldemolins et al, 2011). 
2.12.1 Area under the curve (AUC) 
The activity of vancomycin has a time-dependant killing effect on gram positive bacteria. 
It has, however, been shown that under the same experimental conditions the higher 
the vancomycin concentration, the longer the post antibiotic effect (Vandecasteele et al, 
2013). Therefore its efficacy is best predicted by the 24 hour area under the time curve 
(AUC0-24) divided by the minimum inhibitory concentration (MIC) (Pacifici & Allegaert, 
2012). The MIC is defined as the lowest concentration of an antimicrobial agent that is 
required to inhibit the visible growth of a microorganism in vitro, after overnight 
incubation (Gould et al, 2008). 
 
Lutsar et al (2010) state that the target AUC0-24/MIC ratio for vancomycin is 400 and can 
only be achieved with a dose of 60mg/kg/day if the MIC for S.aureus is ≤2mg/l (Lutsar & 
Metsvaht, 2010). If the MIC of S.aureus is found to be >2mg/ml alternative glycopeptide 
therapy should be considered to avoid possible resistance (Lutsar & Metsvaht, 2010).  
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The susceptibility breakpoint for MRSA lays within a minimum inhibitory concentration 
(MIC) of 2µg/ml, therefore the risk for resistance increases as the MIC of vancomycin 
falls below the 2µg/ml breakpoint (Gould et al, 2008). 
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2.13 Therapeutic drug monitoring of vancomycin 
The above mentioned pharmacokinetic and pharmacodynamic parameters play an 
important role in the therapeutic drug monitoring (TDM) of vancomycin.  
 
Pharmacokinetic studies demonstrate a variability of TDM that is partially explained by 
weight, age and creatinine levels (Pacifici & Allegaert, 2012). This variability explains 
the reasoning behind the implementation of TDM of vancomycin trough levels - ensure 
the effectiveness of therapy as well as the minimisations of toxicity (Pacifici & Allegaert, 
2012).  
 
Therapeutic drug monitoring of vancomycin is crucial due to its nephrotoxic potential 
when the trough concentration is above 10µg/l (Marqués-Minana et al, 2010). Trough 
values below 5µg/l have the potential to cause micro-organism resistance (Marqués-
Minana et al, 2010). Nephrotoxicity is associated trough levels above 10µg/ml, 
concurrent therapy with aminoglycosides and prolonged therapy exceeding 21 days 
Concurrent treatment with amphotericin B and furosemide, existing renal failure and a 
high total dose of vancomycin also plays a role in nephrotoxicity (Pacifici & Allegaert, 
2012). These two studies performed in premature infants and children showed that with 
the correct vancomycin TDM the glomerular and tubular nephrotoxicity could be 
reduced (Marqués-Minana et al, 2010 and Pacifici & Allegaert, 2012)  
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2.14 Vancomycin impurities 
 
Before the 1970s, vancomycin was referred to as “Mississippi mud”, due to its 
impurities. These impurities (crystalline degradation product) were responsible for the 
ototoxicity and nephrotoxicity associated with vancomycin (Somerville et al, 1999).Once 
these were removed the side effects associated with vancomycin were eliminated 
(Somerville et al, 1999). 
 
When exposed to heat over time, vancomycin breaks down into crystalline degradation 
product (CDP-1). Two isomers of CDP-1 exist, CDP-1m (minor) and CDP-1M (major). 
Both of which have no antimicrobial activity. 
 
In vitro at 20-25°C, 50% of the total vancomycin starting weight will be broken down to 
CDP-1 in 16 hours, and 90% is converted to CDP-1 in 40 hours.  To date no 
pharmacokinetic study was performed to determine the half-lives and route of 
elimination of CDP-1(Somerville et al, 1999). 
 
The USP (United States Pharmacopoeia) state that vancomycin should not contain less 
than 88% factor B (active ingredient) and not more than 4% impurities of which CDP-1 < 
2% (Somerville et al, 1999). 
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2.15 Controversy around generic products 
 
According to the World Health Organisation (WHO) two products are therapeutically 
equivalent “if they are pharmaceutically equivalent and after administration in the same 
molar dose, their effects with respect to both efficacy and safety are the same, as 
determined from appropriate bioequivalence, pharmacodynamic, clinical and in vitro 
studies.” (Vesga et al, 2010). 
 
With the introduction of generic formulations into the market, multiple reports of 
impurities and sub-optimal antimicrobial activity have been reported for example, β-
lactam agents, antifungal agents and glycopeptides e.g. vancomycin. In addition there is 
criticism around the world regarding the bioequivalence of generic products (Snyman et 
al, 2009).  
 
In a South African study done by Lowman et al (2011) they found that when comparing 
the generic meropenem with the originator, the generic was equivalent in vitro in terms 
of microbiological activity using the minimum inhibitory concentration (MIC). 
 
Elli Lilly, the originator of vancomycin, discontinued the manufacturing of vancomycin 
end of 2004 (Tattevin et al, 2013). Generic vancomycin products have since emerged in 
the market and are being used all over the world (Nambiar et al, 2012).  
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The efficacy of vancomycin has been questioned since the emergence of vancomycin 
resistance in isolates of Staphylococcus aureus; the increase in vancomycin MICs and 
failure for treating MRSA where the vancomycin MIC > 1.5µg/ml (Tattevin et al, 2013).  
 
In a study done by Vesga et al (2010) it was stated that pharmaceutical equivalence 
does not imply therapeutic equivalence. The study compared three generic formulations 
of vancomycin with the innovator. The neutropenic mouse thigh infection model was 
used to compare the pharmacodynamic properties of the generic formulations of 
vancomycin and the innovator in vivo. In vitro testing was done by both microdilution 
and time-kill curves. It was found that all the generics failed in vivo to kill S.aureus 
(p<0.0001). It was postulated that generics contain less factor B and three times more 
CDP-1 (Vesga et al, 2010). 
 
This study caused intense debate amongst scientific communities, the public and drug 
regulatory authorities.   
 
In the light of the concerns raised with regards to the quality of parenteral vancomycin 
products the US Food and Drug Administration (FDA) investigated the quality of 
vancomycin and its impurities. The investigation focused on high pressure liquid 
chromatography (HPLC) method as stated by the British (BP) and United States 
Pharmacopeia (USP) monographs. The FDA investigation found that factor B was 
between 90-95% and that the impurities were 5-10% and no single impurity was more 
than 2%. The conclusion from this investigation was that all generics used in this study 
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surpassed USP standard for factor B and impurity levels of vancomycin. It was reported 
that the CDP-1 amount present in the generic formulations is of such small amount that 
it will be unlikely to affect the activity of vancomycin, given the antagonistic properties of 
competing for the binding site to D-Ala-D-Ala on the bacterial cell wall (Nambiar et al, 
2012). 
 
A newly published study done by Tattevin et al (2013) compared six generic 
vancomycin formulations on a rabbit model of aortic valve endocarditis induced with a 
MRSA strain. In vitro no significant difference was observed in time-killing curve studies 
with the six generic vancomycin formulations.   
 
It was found that the mean peak concentration was above 35µg/ml and the mean trough 
concentration was below 10µg/ml. Treatment guidelines stipulate that for adults the 
serum trough levels must range between 15-20µg/ml and for premature infants between 
5-10µg/ml. The AUC/MIC (0-24) was 369 with a dosage of 60mg/kg 12 hourly. This is 
below the recommended AUC/MIC (0-24) ≥400 for clinical efficacy (Tattevin et al, 2013). 
 
It is necessary to test the assumption that generic formulations are not only 
pharmaceutically equivalent, but also therapeutic equivalent to the innovator. 
Pharmacokinetic studies in premature infants have not been performed to determine the 
therapeutic equivalence of generic formulations. 
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2.16 Experimental hypothesis 
There is a difference between the trough levels of two commonly used vancomycin 
formulations with regards to: 
a) the correlation with clinical parameters,  
b) the therapeutic range of trough plasma concentrations of vancomycin, and 
c) and clinical treatment outcomes. 
2.17 The Null hypothesis 
There is no difference between the trough levels of two commonly used vancomycin 
formulations with regards to: 
a) the correlation with clinical parameters,  
b) the therapeutic range of trough plasma concentrations of vancomycin, and 
c) and clinical treatment outcomes. 
2.18 Research questions 
2.18.1Is there a correlation between trough level 1 and clinical parameters observed, in 
the two vancomycin formulations?  
2.18.2 What is the difference between the therapeutic ranges of the trough levels of the 
two vancomycin formulations? 
2.18.3 What is the difference in clinical treatment outcomes between the two 
vancomycin formulations?  
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2.19 Objectives of the study 
The objectives of this study are: 
1. To compare vancomycin serum trough levels between the two generic 
formulations of vancomycin in a selected premature infant population with regards 
to: 
d) the correlation with clinical parameters,  
e) the therapeutic range of vancomycin serum trough levels of vancomycin, and 
f) the clinical treatment outcomes. 
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3.1 Study design 
The study was designed as a prospective, comparative, double blinded randomised 
study comparing the trough levels of two generic formulations of vancomycin in a 
selected preterm infant population 
 
3.2 Study site 
The study was conducted at Netcare Blaauwberg and N1City hospitals. Netcare is the 
largest provider of health care in both South Africa and the United Kingdom and was  
founded in 1996. 
 
3.3 Inclusion criteria 
Infants were  included in the study if  they complied with the following criteria: 
Chapter 3 Research 
design and methodology 
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a. All Infants with a corrected post menstrual age between 29-35 weeks admitted in 
the Neonatal Intensive care unit (NICU) with suspected nosocomial infection 
warranting vancomycin as per the discretion of the attending physician (28). 
 
Early antenatal ultrasound was used to determine gestational age, and when not 
available, the new Ballard score was used.   
 
b. Informed and written parental consent for each infant enrolled in the study 
3.4 Exclusion criteria 
An infant was excluded from the study when he/she had the following: 
 Renal dysfunction 
Chromosomal abnormalities or  in extremis 
Concomitant treatment with a drug known to interact with vancomycin 
Refusal of consent by parents (Die numering het hier vreemde goed gedoen…) 
3.5 Randomisation 
The two study groups were divided into vancomycin A and vancomycin B. Each vial’s 
original label was obscured and a new label was created to state the expiring date, the 
batch number and the strength of the vancomycin vial. As per computer generated 
(http://www.random.org/sequences/), numbers were randomly allocated to each of the 
two study groups by an external person. The envelopes contained 1x500mg vial 
vancomycin “A” or “B’, three sticky labels indicated that the patient was on the 
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vancomycin trial to be stuck onto the patient’s prescription chart, and one non-sticky 
label indicating that the patient was on the vancomycin trial and to be placed into 
patient’s medication file. The envelopes were sealed and two independent signatures 
signed the envelopes, therefore preventing from being tampered. Each envelope was 
given a number that corresponded with the computer generated number. The envelopes 
were randomised and sealed, thereby allocating the infant to either one of the two 
formulations of vancomycin. The attending physician drew an envelope as an infant met 
with the inclusion criteria. The physician was blinded to the vancomycin formulation.  
Each participant was allocated a study number (envelope number) to ensure patient 
confidentiality. 
 
Each vial of 500mg vancomycin was reconstituted with 10ml water for injection to make 
a solution of 50mg/1ml and administered as per Neonatal Intensive Care Unit (NICU) 
protocol. The 500mg vancomycin vial was administered at 15mg/kg  twelve hourly as 
per formulary via peripheral intravenous line over 60 minutes by a registered nurse at 
the NICUs. 
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3.6 Anthropometrics 
 
The collected demographics of the study population included the post menstrual age 
(PMA), chronological age, also referred as postnatal age (PNA), gestational age (GA), 
gender, birth weight, weight at trial entry, height at trial entry, serum creatinine levels, 
GFR and albumin levels. 
 
3.7 Biological parameters to be assessed 
 
All blood sampling took place under standard clinical guidelines and no additional blood 
was taken for study purposes.  
 
When a MRSA infection was suspected, C-reactive proteien (CRP) levels were 
collected. Procalcitonin (PCT) levels were taken upon discretion for the physician. 
 
Albumin and serum creatinine levels were collected as per NICU protocol. 
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3.8 Blood sampling procedures  
 
Blood sample of 0.3-0.4ml was collected in a BD Mirotrainer SST ™ tube (Becton, 
Dickinson & Company, Frankin Lakes, NJ, 07417, USA), allowed to clot and then 
centrifuged to separate the clot from the serum. 
 
 Sampling for vancomycin trough levels was done thirty minutes before the 
administration of the third dose of vancomycin by a registered nurse from both the 
NICUs at Netcare Blaauwberg Hospital and N1City Hospital. The samples were 
transported to the Ampath-Davies laboratory at N1City, Cape Town for analysis. 
 
3.9 Plasma trough concentrations determination 
 
The Architect™ c1600 System from Abbott Laboratories was used to do the particle-
enhanced turbidimetric inhibition immunoassay (PETINIA). The lower quantification limit 
is 1.1µg/l. The serum trough levels were interpreted by attending microbiologist at 
Ampath-Davies, N1 City, Cape Town. The results were sent to the attending physician 
for continued clinical management and for data collation by the study group.  
 
Data were collected in the NICUs at Netcare Blaauwberg and N1 City. Data were 
obtained from the each infant’s patient file, nursing and physician notes.  
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3.10 Treatment outcomes 
When a premature infant showed signs of sepsis the physician prescribed meropenem 
and vancomycin concurrently. Whereas vancomycin was to treat suspected MRSA and 
meropenem was to treat suspected gram negative bacteria.  
Vancomycin treatment was discontinued after two negative CRP values and a negative 
blood culture. Premature infants were discharged from the NICUs on the physicians’ 
discretion and clinical improvements.  
 
3.11 Statistical analysis 
3.11.1 Sample size  
Using the statistical analysis computer program SAS® 9.3, 2011, USA, estimation was 
made giving an indication of how many infants will be needed to make the study 
statistically significant.  
 
Assuming a difference of three units is clinically important. , that a difference will be 
detectable with better than 80% power based on a two-sample t-test with a two-sided 
alternative hypothesis and a significance level of 0.05 when the actual standard 
deviation is 1.5 units. Therefore the number of patients needed is nine in each study 
group.  
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3.11.2 Data analysis 
Data analysis was performed by the SAS® 9.3 program and Pearson correlation 
coefficients were used to compare the trough levels with variables and pooled t-test 
were performed to determine the p-values. Given p=0.05 being scientifically significant. 
 
3.12 Ethical consideration 
 
Ethical approval was obtained from the Ethics Committee of the University of Western 
Cape for this study (Certificate registration no. 12/2/21). Permission to conduct the 
study in Netcare hospitals were obtained from the Research Department of Netcare 
(Reference no. (UNIV-2012-0008). 
Informed consent was obtained from the parents of each premature infant enrolled into 
the study. 
The study was done in accordance with Helsinski Declaration and confidentiality was 
observed. 
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3.13 Dissemination of research results 
The study results would be disseminated through the following: 
 
1. Presentation of results at the School of Pharmacy, University of Western Cape,  
2. Poster presentation at the Three’s Company Conference 2013. 
3. Publication in a relevant scientific journal 
4. Thesis for Master’s degree at the University of the Western Cape. 
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4.1 Study population  
4.1.1 Patient demographics 
The study was conducted from April 2012 to July 2013. It involved 19 premature infants who met 
study inclusion criteria. The patient demographics, dose/body weight, serum albumin levels, serum 
creatinine levels and the glomerular filtration rate (GFR) are summarised in Table 4.1 (n=10) for the 
Aspen Vancomycin CP® group (AV) and in table 4.2 (n=9) for the Sandoz Vancocin CP® group (SV).    
Ten premature infants (50% male and 50% female) were randomly included in AV group and 9 
premature infants (33% male and 66% female) SV group.  
 
Chapter 4 Results 
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Table 4.1: Summary of Aspen Vancomycin ® patient demographics, dose/body weight, serum albumin levels, 
serum creatinine levels and glomerular filtration rate.  
Study 
number  
Gender Gestational 
age 
(Weeks) 
Birth 
body 
weight 
(g) 
Post 
natal 
age 
(days) 
Post 
menstrual 
age 
(weeks) 
Body 
weight 
at trial 
entry 
(g) 
Height 
at trial 
entry 
(cm) 
Dose/ 
Body 
weight 
(15mg/kg) 
Serum 
albumin 
levels 
(g/l) 
Serum 
creatinine  
(mmol/l) 
Glomurular 
filtration 
rate (GFR) 
(ml/min) 
1 M 32 2130 7 33 2080 45 31.95 24 0.39 38 
2 F 32 2690 18 34.57 2615 45 35 32     
3 M 31 1710 9 32.29 1660 44 25.6 27 0.22 65 
6 M 30 1640 17 32.43 1850 36 27.8 24     
7 M 28 940 18 30.57 1080 38 16.2 19 0.26 48 
11 F 32 1390 7 33 1490 45 22.4 34 0.28 53 
12 F 32 1230 7 33 1250 41 18.8 34 0.38 35 
15 F 33 1170 3 33.42 1170 46 26.5 28 0.21 72 
9 M 28 1270 14 30 1300 28 19.5 24 0.12 74 
17 F 32 1585 7 33 1585 48 23.8 32 0.33 47 
Median  32 1487.5 8 33 1537.5 44.5 24.7 27.5 50.5 0.27 
Range  28-33 
940-
2690 3-18 30-34.6 
1080-
2615 28-48 18.8-31.95 19-34 35-74 0.12-0.39 
 
 
 
 
 
Chapter 4: Results 
 
45 
 
Table 4.2: Summary of Sandoz Vancocin CP® patient demographics, dose/body weight, serum albumin levels, 
serum creatinine levels and glomerular filtration rate.  
Study 
number  
Gender Gestational 
age  
 
(Weeks) 
Birth 
body 
weight 
 
(g) 
Post 
natal 
age 
 
(days) 
Post 
menstrual 
age 
(weeks) 
Body 
weight 
at trial 
entry 
(g) 
Height 
at trial 
entry 
(cm) 
Dose/body 
weight  
(15mg/kg) 
Serum 
albumin 
levels 
(g/l)  
Serum 
creatinine   
(mmol/l) 
Glomurular 
filtration 
rate (GFR) 
(ml/min) 
4 F 34 2015 5 34.71 1855 45 30   50 0.297 
5 F 29 925 36 34.14 1115 39 16.7 25 60 0.214 
8 F 28 775 30 32.28 925 32 13.8 34 50 0.211 
10 M 26 680 43 32.14 980 36 14.7       
13 F 26 910 35 31 1165 36 17.5 37 39 0.304 
14 M 33 1160 3 33.42 1150 40 17.4 23 52 0.254 
16 M 30 1450 11 31.57 1480 42 22.2 22 53 0.262 
18 F 23 630 58 31.28 1830 40 27.5 27 26 0.507 
19 F 31 1590 18 33.57 1640 43.5 24.5 23 61 0.235 
Median  29 925 30 32.28 1165 40 17.5 25  51 0.258 
Range  26-34 
630-
2015 3-58 31-34.7 
925-
1855 32-45 13.8-27.5 22-37  26-61 0.211-0.507 
 
The results are presented as the median and range. 
In the AV group the median (range) gestational age (GA), post natal age (PNA) and postmenstrual 
age (PMA) were 32 (28-33) weeks, 8 (3-18) days and 33 (30-34.6) weeks respectively. The median 
(range) birth body weight, body weight at trial entry and height at trial entry were 1487.5 (940-2690) g, 
1537.5 (1080-2615) g and 44.5 (28-48) cm respectively. 
In the SV group it was found that the median (range) GA, PNA and PMA were 29 (26-34) weeks, 30 
(3-58) days and 32.28 (31-34.7) respectively. The median (range) birth body weight, weight at trial 
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entry and height at trial entry were 925 (630-2015) g, 1165 (925-1855) g and 40 (32-45) cm 
respectively.  
For the AV group the median (range) albumin, serum creatinine and GFR are 27.5 (19-34) g/l, 50.5 
(35-74) mmol/l and 0.27 (0.12-0.39) ml/min/1.73m2 respectively. 
The median (range) albumin, serum creatinine and GFR are 25 (22-37), 51 (26-61) and 0.26 (0.21-
0.51) respectively for the SV group 
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Table 4.3:  Comparison of patient demographics as per study group.   
Demographics n Aspen-Vancomycin (AV) 
 
(Median) 
Range N Sandoz-Vancocyn (SV) 
 
(Median) 
Range p-value 
GA (weeks) 10 32 28-33 9 29 23-34 0.202 
BBW 
(g) 
10 1488 940-2690 9 925 630-2015 0.061 
PNA (days) 10 8 3-18 9 30 3-58 0.102 
PMA (weeks) 10 33 30-34.6 9 32.28 31-34.7 0.936 
 
Weight at trial entry (g) 10 1538 1080-2615 9 1165 925-1855 0.195 
Height at trial entry (cm) 10 44.5 28-48 9 40 32-45 0.179 
Key: GA=gestational age; BBW=birth body weight; PNA=postnatal age; PMA=postmenstrual age 
Table 4.3 compares the patient demographics as per study group. Non-parametric tests are used 
when the sample sizes are small, since these techniques are distribution-free techniques and 
therefore do not have any assumptions of underlying distributions of the data. Wilcoxon Two-Sample 
Test (Two-sided) was used to determine the p-values. The p-value is indicated for each parameter 
compared. Since all p-values are higher than 0.05 (5% significant level), there is no significant 
difference between the two study groups regarding GA, BBW, PNA, PMA, weight at trial entry and 
height at trial entry.
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4.1.2 Biological parameters  
Table 4.4: Comparison of biological parameters as per study group.  
 Aspen-Vancomycin CP® (AV) Sandoz – Vancocin ® (SV) p-value 
Biological parameters n (Median) 
 
Range n  (Median) Range 
Albumin (g/l) 
 
10 27.5 19-34 7 25 22-37 0.696 
Serum creatinine concentration (mmol/l) 
 
8 50.5 35-74 8 51 26-61 0.757 
Glomerular filtration rate 
 (GFR) 
(ml/min/1.73m
2
) 
 
8 0.27 0.12-0.39 8 0.26 0.21-0.51 1.00 
Normal values: Albumin – PMA:  29-33 weeks = 22-35g/l; Serum creatinine - >130µmol/l indicative of renal impairment; 
 GFR: PMA 30-32 weeks = 0.3-1.3 and PMA 33-35 = 0.5-1.5 
 
Table 4.4 compares the biological parameters viz. the albumin levels, serum creatinine concentration 
and GFR, of each of the study groups. The results are presented as the median (range).    
Since p-values are higher than 0.05 (5% significant level), there is no significant difference between 
the two groups regarding the albumin levels, serum creatinine concentration and GFR. 
 
 
 
 
 
 
 
Chapter 4: Results 
 
49 
 
Figure 4.1: Comparing albumin levels with trough level 1 in AV and SV 
 
Figure 4.1 compares the relationship between trough level 1 and the albumin levels taken per 
premature infants in both study groupes. The premature infants in the AV group is represented by the 
blue line, and those in the SV group with the red line. Eighty four percent of premature infants had an 
albumin level taken. It can be observed that there is a lower trend towards albumin levels observed in 
the SV group.
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Comparison of trough levels assessed 
Table 4.5: Comparison of trough level 1 as per study group 
 Aspen – Vancomycin (AV) Sandoz-Vancomycin (SV) p-value 
Trough levels n  (median) 
 
Range N  (median) 
 
Range 
Trough 1 
(µg/ml) 
10 11.5 8-19 9 10 1-14 0.118 
 
In table 4.5 trough levels 1 of both study groups were compared. Trough levels were collected for 
each premature infant depending on the severity of the illness and the duration of the vancomycin 
therapy, as per discretion of the attending physician. The results are presented as median (range).  
 Wilcoxon Two-Sample Test (Two-Sided) was used to determine the p-value. Since the p-value is 
larger than 0.05 (5% significant level), there is no significant difference between trough level 1 of the 
two study groups. 
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Figure 4.2: Comparing trough level 1 in AV and SV 
 
Figure 4.2 compares trough level 1 observed in premature infants in AV (blue line) and SV (red line).   
There is a trend towards a lower trough level 1 in the SV group when compared to with those in the 
AV group. 
Trough level 2 and 3 were measured at the physician’s discretion and not 60 minutes before the sixth 
and ninth dose respectively, as per study protocol. Therefore it could not be included in this study.
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4.3 Correlations between parameters assessed and trough levels 1 
Table 4.6: Correlations between clinical parameters and trough level 1 in each study group. 
Clinical parameters 
Aspen Vancomycin 
(n=10) 
Sandoz Vancomycin 
(n=9) 
 
r-value p-value r-value p-value 
GA (weeks) 0.01 0.971 0.89 0.0013 
BBW (g) -0.28 0.432 0.71 0.031 
PNA (days) 0.19 0.594 -0.73 0.026 
PMA (weeks) 0.06 0.877 0.903 0.0008 
Body weight at trial entry (g) -0.34 0.344 0.017 0.966 
Height at trial entry (cm) -0.02 0.960 0.39 0.291 
Albumin (g/l) -0.07 0.845 -0.37 0.410 
Serum Creatinine (mmol/l) -0.02 0.955 0.43 0.291 
GFR (ml/min/1.73m2) 
 -0.12 0.779 -0.46 0.257 
Key: GA=gestational age; BBW=birth body weight; PNA=postnatal age; PMA=postmenstrual age; r=correlation coefficient 
The actual trough levels 1, not the average, were correlated by Spearman’s rank order correlation for 
GA, BBW, PNA, PMA, bodyweight at trial entry, height at trial entry, serum albumin levels, serum 
creatinine levels and GFR. Table 4.6 describes the correlations found. 
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There was no correlation between any of the parameters assessed and AV trough level 1. 
Though it was found that there is a strong positive correlation between SV trough level 1 and GA 
(r=0.89; p=0.0013), BBW (r=0.71; p=0.031), and PMA (r=0.903; p=0.0008), a negative correlation 
was found between SV trough level 1 and PNA (r=-0.73; p=0.021). No correlation was found between 
the body weight and height at trial entry (r=0.017; p=0.961 and r=0.39; p=0.291) respectively. 
No correlation was found between SV trough level 1 and the following biological parameters albumin 
(r=-0.37; p=0.41) serum creatinine (r=0.43; p=0.291) and GFR (r= -0.63; p=0.257).  
Figure 4.3: Scatter plots comparing trough level 1 and gestational age (GA) of both study groups. 
=  
When SV is considered (the red dots), it is clear that there is a good positive trend. For this reason, a 
significant correlation(r=0.89; p=0.0002) is found between GA and trough level 1 for the SV group. In 
AV: r=0.01; p=0.971 
SV: r=0.89; p=0.0002 
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the AV group, two observations have much higher values for trough level 1 than the rest (see 
encircled blue dots). These two values ensure that the correlation between these two variables are 
not significant (r=0.01; p=0.971)for the AV group.  
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Figure 4.4: Scatter plots comparing trough level 1 and birth weight (BW) of both study groups. 
 
The values of AV are scattered, thus no good correlation (r=-0.28; p=0.432) is found for this group 
between the birth weight and trough level 1. 
There is a positive correlation (r=0.711; p0.031) between birth weight and trough level 1 in the SV 
group. 
 
 
 
AV: r= -0.28; p=0.432 
SV: r= 0.711; p=0.031 
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Figure 4.5: Scatter plots comparing trough level 1 and PNA of both study groups 
 
The values of AV are scattered, no clear trend is visible, thus no significant correlation(r=0.19; 
p=0.594) is found for this group between PNA and trough level 1. It is clear that there is a negative 
correlation (r=0.73; p=0.026) between these two variables for SV.  
 
 
 
AV: r=0.19; p=0.594 
SV: r=-0.73; p=0.026 
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Figure 4.6: Scatter plots comparing trough level 1 and PMA of both study groups. 
 
The presence of the two outlyers in the AV group is the reason that there was no correlation found 
between the PMA and trough level 1.   
A strong positive correlation (r=0.90; p=0008) was found between the PMA and trough level 1 in the 
SV group. 
AV: r=0.06; p=0.877 
SV: r=0.90; p=0.0008 
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4.4 Therapeutic ranges of trough level 1 in both study groups 
Table 4.7: Distribution of premature infants with regards to trough level 1 being below minimum therapeutic 
serum concentration (<5 µg/ml l), within serum therapeutic range (5-10 µg/ml) and above minimum toxic serum 
concentrations (>10mg/l) in both study groups 
 <5 µg/ml  5-10 µg/ml  >10 µg/ml  Total 
Aspen 
Vancomycin® 
(AV) 
0 
0% 
3 
30% 
7 
70% 
10 
Sandoz 
Vancomycin CP® 
(SV) 
2 
22.22% 
4 
44.44% 
3 
33.33% 
9 
Total 2 7 10  
 
Table 4.7 above describes the number (top) and percentage (bottom) of premature infants whose 
trough level 1 were below minimum effective concentration (<5 µg/ml), within therapeutic range (5-10 
µg/ml) and above minimum toxic serum concentration (>10 µg/ml) in both study groups. 
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Figure 4.7: Distribution of premature infants that had a trough level 1 below the minimum effective 
concentration (<5 µg/ml) for each study group  
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Figure 4.7 describes those premature infants with trough level 1s that were below the minimum 
therapeutic serum concentration. The two squares indicate that both the premature infants received 
SV. No additional trough levels were taken for these two premature infants as per the physician’s 
discretion. Therapy was discontinued after trough level 1 in both premature infants.   
 
 
Distribution of premature infants that had a trough level 1 below the minimum 
therapeutic concentration (<5 µg/ml) for each study group (n=2). 
(Solid blue line with circles=AV and d tted gr en line with squares = SV) 
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Figure 4.8: Distribution of premature infants that had a trough level 1 within therapeutic range (5-10 µg/ml) for 
each study group 
 
trough
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
atime
1 2 3 4 5 6
Trough pattern for each Level
Green Squares=Sandos, Blue Dots=Aspen
y=In range
id 1 8 9 10 16 17 19
 
Figure 4.8 describe those premature infants that had a trough level 1 within therapeutic range and the 
placement of trough level 2 and 3 respectively.  
The dotted green line and squares indicate those premature infants that received SV and the solid 
blue line with the circles indicates those infants that received AV.   
For the study population it was found that all seven premature infants (4 received SV and 3 received 
AV) had though level 1 within therapeutic range also had the second  trough level within therapeutic 
range. Four out of the seven (57%) premature infants (3 SV and 1 AV) had the third trough level 
within therapeutic range. Two of the seven (29%) premature infants (1 SV and 1 AV) had the third 
Distribution of premature infants that had a trough level 1 within the therapeutic range 
(5-10 µg/ml) for each study group (n=7). 
(Solid blue line with circles=AV and dotted green line with squares = SV) 
 
S
e
ru
m
 t
ro
u
g
h
 l
e
v
e
l 
c
o
n
c
e
n
tr
a
ti
o
n
s
 (
m
g
/l
)  
Time (days) 
 
 
 
 
Chapter 4: Results 
 
61 
 
trough level above the minimum toxic concentration and one premature infant (SV) (14%) had the 
third trough level below the minimum effective concentration. 
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Figure 4.9: Distribution of premature infants that had a trough level 1 above the minimum toxic serum 
concentration (>10 µg/ml) n=10. 
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Figure 4.9 describes premature infants that had a trough level 1 above the minimum toxic serum 
concentration (>10µg/ml) and the results of trough level 2 and 3 respectively. 
It was found that ten out if 19 (52%) premature infants had trough level 1 above the minimum toxic 
serum concentration. Seven (36%) premature infants received AV and three (15%) received SV. 
Out of the seven premature infants that received AV, five had a second trough level taken. Therapy 
was discontinued as per the physician’s discretion in two of those seven premature infants before a 
second trough level could have been taken. Out of the five premature infants that had a second 
Distribution of premature infants that had a trough level 1 above minimum toxic serum 
concentration (>10 µg/ml) for each study group (n=10). 
(Solid blue line with circles=AV; Dotted green line with squares = SV) 
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trough level taken, two had a second trough level within therapeutic range and three had the second 
trough level above the minimum toxic serum concentration. Out of the seven premature infants that 
received AV, only two had a third trough level taken and it was also above the minimum toxic 
concentration. Both those premature infants had all three trough levels above the minimum toxic 
serum concentration. 
The three premature infants that received SV had a second trough level taken. Two premature 
infants’ second trough level was above the minimum toxic concentration and one was within 
therapeutic range. Both those premature infants had a third trough level within therapeutic range. 
Therapy was discontinued as per the physician’s discretion in one premature infant after the second 
trough level was taken. 
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4.5  Treatment outcomes of the both study groups 
Table 4.8: Treatment outcomes of Aspen-Vancomycin® premature infants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median 
 
39.5 
 
36.5 
 
2127.5 
 
Range 
 
(26-167) 
 
(36-54) 
 
(1835-
4040) 
Key: LOS=Length of stay; GA= Gestational age; NEC= nectrotising enterocolitis CRP=C-reactive protein; 
PCT=Procalcitonin; NV=normal value 
 
Premature 
infant 
study no. 
LOS 
(days) 
Corrected 
GA at 
discharge 
(weeks) 
Body 
weight at 
discharge 
(g) 
Blood 
culture 
Reason for 
vancomycin 
treatment 
Treatment 
duration 
(doses)  CRP (NV:<5) 
PCT (NV:0-
0.05ng/ml) 
              
Day 
1 
Day 
2 
Day 
3  
Day 
4 
 Day 
1 
Day 
2 
Day 
3 
1 26 36 2390 Negative 
Presumed 
line related 
sepsis 6 3 <1 <1   0.2 0.35 
 
2 27 36 3100 Negative 
Presumed 
line related 
sepsis 3 3   <1   0.17   
 
3 31 35 2110 Negative Sepsis, ileus 6       <2 0.45 0.24 
 6 167 54 4040 Negative NEC 9 35 
 
31 29 
   
7 61 37 1900 Negative 
Abdominal 
mischief 7 2 2     0.3 0.43 
 
11 42 39 2055 Negative 
Abdominal 
mischief 7 <2 <2         
 
12 42 39 1835 Negative 
Abdominal 
mischief 7 <2       0.16   
 
15 24 36 2030 Negative 
Presumed 
line related 
sepsis 7 4 3         
 
9 55 36 2145 Negative 
Presumed 
line related 
sepsis 6     7   0.33   0.29 
17 
 
 37 37 2155 Negative 
Abdominal 
mischief 6 8 <5 3         
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Table 4.8 describes the LOS, corrected GA at discharge and the premature infant’s weight at 
discharge for study group AV. It also describes blood culture, the reason for treatment, duration of 
treatment, the CRP (Day1-4) and PCT values (Day1-3). It was found that four (40%) infants were 
treated for presumed line related sepsis, four (40%) were treated for abdominal mischief, one (10%) 
was treated for NEC and one (10%) was treated for sepsis associated with ileus. 
The median (range) length of stay (LOS) was 39.5 (26-167) days, corrected gestational age and the 
body weight at discharge for AV was 36.5 (36-54) weeks and 2127.5 (1835-4040) g respectively. 
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Table 4.9 Treatment outcomes of Sandoz-Vancocin CP® premature infants 
Premature 
infant 
study no. 
LOS 
(days) 
Corrected 
GA at 
discharge 
(weeks) 
Body 
weight at 
discharge 
(g) 
Blood 
culture 
Reason for 
vancomycin 
treatment 
Treatment 
duration 
(doses) 
CRP (NV:<5) PCT (NV:0-
0.05ng/ml) 
              Day 1 Day 
2 
Day 
3  
Day 
4 
 Day 1 Day 
2 
Day 
3 
4 13 36 1930 Negative Presumed IV 
line sepsis 
8 14    0.41    
5 77 40 2000 Negative  Sepsis and 
abdominal 
distention 
9 107 82 30      
8 75 38 1825 Negative Abdominal 
mischief 
10 <1 <1   0.14 0.16   
10 82 37 1822 Negative Abdominal 
mischief 
9 7 2   0.16    
13 70 36 1925 Negative Abdominal 
mischief 
5 <2    0.17    
14 37 38 1820 Negative Presumed IV 
line sepsis 
9 44 10 8  0.53 0.26 0.16
  
16 39 35 2000 Negative Abdominal 
mischief 
7 4 9 6  0.34 0.15   
18 122 41 2495 Negative Pneumonia 5 <2    0.1    
19 35 36 2120 Negative Abdominal 
mischief 
10 23 37 15  2.8    
 
Median 70 37 1930 
Range 13-122 35-41 1820-2495 
Key: LOS=Length of stay; GA= Gestational age; CRP=C-reactive protein; PCT=Procalcitonin; NV=normal value 
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Table 4.9 describes the LOS, corrected GA at discharge and the premature infant’s weight at 
discharge for study group SV. It also describes blood culture, the reason for treatment, duration of 
treatment, the CRP (Day1-4) and PCT values (Day1-3). 
It was found that two  (22%) infants were treated for presumed line related sepsis, five  (55%) were 
treated for abdominal mischief, one  (11%) was treated for pneumonia and one  (11%) was treated for 
sepsis and abdominal distension.   
The median (range) LOS is 70 (13-122) days; corrected gestational age and body weight at discharge 
for SV were 37 (35-41) weeks and 1930 (1820-2495) g respectively. 
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The aim of this prospective, double blind and randomised study is to compare the 
trough plasma levels (Cmin) of two vancomycin preparations available in South Africa 
(Aspen-Vancomycin and Sandoz-Vancocin) in a selected premature infant population 
presenting with suspected MRSA infection. Similarities between patients’ demographic 
and pathophysiological profiles have been confirmed. 
5.1 Patient demographics 
The sample size (n=19) and demographic parameters of premature infants involved in 
this study are similar to that of premature infants included in previous studies. The 
studies conducted by Reed et al, McDougal et al, De Hoog et al and Asbury et al 
involved 15, 15, 22 and 19 premature infants respectively. 
In this study the median (range) GA was 32 (28-33) weeks in the AV group and 29 (23-
34) weeks in the SV group. This is similar to the GA of premature infants in previous 
studies, (Reed et al 28.4 ± 2.6 weeks, McDougal et al 29.4 ± 2 and De Hoog et al 29 
(25-42) and Ashbury et al 29.3 ± 4.2 weeks). 
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The median (range) PNA of the premature infants in the AV group was 8 (3-18) days 
and in the SV group was 30 (3-58) days. This is similar that was found in previous 
studies where the PNA was 20.5 ± 10.4 in Reed et al , 23 ± 14 in McDougal et al, 11 (7-
21) in De Hoog et al, and 33.9 ± 19.9 days in Asbury et al. 
The median (range) PMA in this study was 33 (30-34.6) and 32 (31-34.7) weeks for AV 
and SV respectively. This is similar to premature infants involved in previous studies 
(Asbury et al, 1993; McDougal et al, 1995). 
The weight at trial entry for the premature infants in the AV and SV group was 1537 
(1080-2615) g and 1165 (925-1855) g respectively and is similar to that of premature 
infants included inprevious studies done by Reed et al. (1069 ± 435g), McDougal et al 
(1194 ± 412g), De Hoog et al (1160 (730-3420g) and Ashbury et al (1780 ± 1080g). 
The recommended dose for premature infants with a PMA of 29-34 weeks is 15mg/kg  
twelve hourly (Horn et al, 2007; Gibbon et al 2005). Dosing schedules in the literature 
do however differ - De Hoog et al (10mg/kg Q8h), Reed et al (12.6mg  twenty four 
hourly) and McDougal et al (18mg/kg eighteen hourly). 
As indicated in table 4.3 there was no significant statistical difference between GA, 
BBW, PMA, PNA and weight at trial entry in the premature infants enrolled in the AV 
group when compared with those of the SV group. 
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5.2 Patient biological parameters 
As indicated in table 4.4 there was no significant statistical difference between serum 
creatinine concentration, GFR and albumin, of the premature infants enrolled in AV 
group and those of the SV group. 
The median (range) serum creatinine for the premature infants in the AV group was 
50.5 (35-74)mmol/l and 51 (26-61)mmol/l for those in the SV group.  This serum 
creatinine concentration is similar to that found in premature infants by Grimsley & 
Thomson (1999) where the median serum creatinine concentration was 49 (18-172) 
mmol/l.  
Albumin levels were measured for eighty four percent of all study premature infants. 
Although no statistically significant difference (p=0.696) could be found between the AV 
(n=10) and SV (n=7) group, there was a trend towards a lower albumin level in the SV 
group (see figure 4.1). Vancomycin is 50-55% albumin bound and it was found that  with 
an increase in serum albumin levels, the lower the vancomycin serum trough levels, 
(Sun et al,1993, Jackson et al, 1999) 
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5.3. Comparison of trough levels assessed as per study group 
There was no significant statistical difference (p=0.118) between trough level 1 in the 
AV and SV groups. 
Trough levels 2 and 3 were collected, but were not statistically assessed due to failure 
to study protocol. The levels were not collected strictly sixty min before the sixth and 
ninth dose but at the physician’s discretion. Vancomycin dosing schedules were 
amended by the attending physician due to the previous trough level being considered 
inappropriate. The following dose was omitted therefore the next trough level being not 
in line with study protocol. 
The median vancomycin serum trough level 1 was 11.5 (8-19)µg/ml and 10 (1-14)µg/ml 
for AV and SV respectively. This correlates with what was found by De Hoog et al (8.2 ± 
2.2µg/ml with a dose of 15mg/kg twelve hourly).  McDougal et al found serum trough 
levels of 3.9 ± 0.6µg/ml with a dose of 18mg/kg eighteen hourly.   
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5.4 Correlations between clinical parameters and trough level 1 in each 
study groups 
No correlation between any clinical parameters, (demographic or biological) was found 
in the AV group. A strong positive correlation was observed between trough level 1 and 
the GA (r=0.89; p=0.0013), BBW (r=0.71; p=0.031), PMA (r=0.903; p=0.0008) and a 
strong negative correlation was observed between trough level 1 and PNA (r=-0.73; 
p=0.026) in the SV group.  
A possible reason for this non-correlation between trough level 1 and biological and 
demographic parameters in the AV group may be the two outlying trough levels when 
compared to these parameters in two study premature infants, as indicated in figures 
4.3-4.6. 
Vancomycin trough levels are dependent on demographic factors (GA, BBW, PMA, 
PNA), biological parameters (S-Cr, Alb, GFR) as well as pharmacokinetic parameters 
(protein binding, Vd, clearance) (De Hoog et al, 2004). This study has shown that the 
first two sets of parameters were not of definitive value in determining trough levels. 
Therefore the possible effect of pharmacokinetic parameters on the vancomycin serum 
trough levels was assessed. 
In literature the protein binding, vancomycin clearance and volume of distribution  have 
an effect on vancomycin serum trough concentration (De Hoog et al, 2004; Bauer et al, 
2008; Pacifici & Allegaert, 2012) 
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5.4.1 Protein binding 
Vancomycin is bound to albumin 50-55% (Sun et al, 1993; Rybak et al, 2009) and to 
serum immunoglobulin A (s-IgA).  The total fraction (bound and unbound) of 
vancomycin is measured in the serum, although only the free fraction is dependent on 
drug clearance (Sun et al, 1993).  
Albumin levels were assessed in this study, but no significant statistical difference was 
observed between the AV and SV group (p=0.686). However, as shown in figure 4.1 
there is as expected, a decreasing vancomycin trough level with an increasing albumin 
level. Despite the non-significance of the difference between SV and AV there seems to 
be a trend towards a lower vancomycin level in the SV group as compared to AV for a 
similar albumin level. The binding effect of vancomycin to other plasma proteins such as 
s-IgA was not investigated in this study. 
 
5.4.2 Vancomycin clearance 
Vancomycin is 80-90% eliminated by the kidneys via glomerular filtration (Rocha et al, 
2006). Renal function and glomerular filtration increases linearly with PMA, due to 
maturation of kidney functions (Rocha et al, 2006; McDougal et al, 1995) and this result 
in an increase in vancomycin clearance (Grimsley & Thompson, 1999) with lower 
vancomycin serum trough levels as a result.  Vancomycin clearance increased with 
PMA and was associated with a greater elimination rate constant and a shorter half life 
(McDougal et al, 1995). 
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Grimsley & Thompson (1999) also found that vancomycin clearance has a positive 
linear correlation with weight and PMA and an inverse relation to the serum creatinine. 
This study found a positive linear correlation (r=0.89; p=0.0013) between trough level 1 
and GA in the SV group. This would clinically imply an increase in renal function 
maturation and therefore a lower trough level 1.   
A negative linear correlation was found (r=-0.73; p=0.026) between trough level 1 and 
PNA in the SV group. Thus with an increase in PNA, trough level 1 decreases. This 
finding can be due to the increase in renal function maturation and therefore an 
increase in vancomycin clearance as PNA increases, therefore a lower trough level 1. 
This finding correlates with what was found in literature (Pacifici & Allegaert, 2012). 
No correlation was found between trough level 1 and either serum creatinine 
concentration or GFR in the current study. Literature has shown that vancomycin 
clearance is inversely related to serum creatinine level by Grimsley & Thompson (1999) 
 
5.4.3 Volume of distribution 
Due to vancomycin’s hydrophilic properties it distributes into total body water and 
extracellular fluid (Ulldemolins et al, 2011).  Premature infants have large extracellular 
fluid volume (80%) thus a large volume of distribution (Marques-Minana et al, 2010; De 
Hoog et al, 2004) resulting in lower than expected serum trough levels. McDougal et al 
found a positive linear correlation between the absolute Vd and the PCA (r=0.79; 
p<0.001), but no difference when Vd was standardized for weight.  No correlation with 
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weight at trial entry was found (r=0.09; p=0.59). This finding was supported by Grimsley 
& Thompson (1999) who also found that PMA and weight influenced the Vd with the 
weight having a more significant effect on the Vd than PMA. 
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5.5 Therapeutic ranges of trough level 1  
In AV group (n=10) no trough level 1 was below the minimum therapeutic serum 
concentration, three (30%) were within therapeutic range and seven (70%) were above 
the minimum toxic serum concentration. 
In SV group (n=9), two (22.2%) premature infants had trough level 1 below the minimum 
therapeutic serum concentration, four (44.4%) were within therapeutic range and three 
(33.3%) were above the minimum toxic serum concentration. 
  
5.5.1 Distribution of premature infants with a trough level 1 below minimum 
therapeutic serum concentration (<5µg/ml)   
Premature infants that had trough level 1 below the minimum therapeutic serum 
concentration were born at 26 and 23 weeks GA respectively. Their weight at trial entry 
was 1165g and 1830g respectively. The PMA at trial entry was 31 and 31.5 weeks 
respectively.  The PNA was 35 and 58 days respectively. Both premature infants 
received SV. No additional trough levels were taken for these premature infants and 
therapy was stopped as per physician’s discretion and per clinical signs. A possible 
explanation for this is the improved renal function due to the advanced PNA that may 
have required an adjustment in the dosing schedule. In a retrospective study done by 
De Hoog et al (2004), 17.6% of infants were found to have vancomycin serum trough 
levels 1 below therapeutic levels, irrespective of dosing schedule used. The study 
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offered no explanation for this finding. It can however only be assumed to be dosing 
schedule related. 
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5.5.2 Distribution of premature infants with a trough level 1 within 
therapeutic range (5-10µg/ml) 
The study will discuss these premature infants by means of two case studies. 
5.5.2.1. Case study 1 
Premature infant number 1 had a trough level 1(5µg/ml) within therapeutic range.  
Trough level 2 (9µg/ml) stayed within therapeutic range, but trough level 3 (16µg/ml) 
was measured above maximum therapeutic serum concentration (>10µg/ml).  This male 
43 days PNA premature infant was admitted into the study at PMA of 32.1 weeks and a 
weight at trial entry of 980g. The infant was intra-uterine growth retarded (IUGR) at birth 
and remained small for gestational age (SGA) at time of study entry. The infant received 
SV.  
A possible explanation for this phenomenon is the IUGR/ SGA (Fenton et al, 2003) 
status of the infant. Renal function in SGA infants has been shown to be immature (Aly 
et al, 2013) thereby increasing the vancomycin trough levels.  
5.5.2.2. Case study 2 
Premature infant number 2 had a trough level 1 (10µg/ml) that was on the border of the 
therapeutic range and decreased to border-line sub-therapeutic at trough level 2 
(5µg/ml) before becoming sub-therapeutic at trough level 3 (4µg/ml). The female 
premature infant was admitted to the trial at a PNA of 18 days and a PMA of 33.5 weeks 
and a trial entry weight of 1640g. The infant received SV. 
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A possible explanation for this finding is the relative maturity of this premature infant. 
She was on full feeds receiving additional protein and calorie supplementation which 
may have altered the serum protein levels (Van den Akker et al, 2007), thereby 
increasing the bound vancomycin level and decreasing the serum trough levels in time. 
The infant was also approaching the 35 week of vancomycin dosing schedule change (8 
hourly instead of 12 hourly) (Horn et al, 2007). Due to renal maturity, an increase in 
renal clearance and therefore a  decreased half-life may also have contributed to the 
decrease of vancomycin trough levels over time (McDougal et al, 1995). 
. 
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5.5.3 Distribution of premature infants with a trough level 1 above the 
minimum toxic serum concentration (>10µg/ml) 
The study will discuss these premature infants by means of two case studies 
5.5.3.1 Case study 3 
This male premature infant received a vancomycin dose of 17mg twelve hourly.  Trough 
level 1 (12 µg/ml) was above the minimum serum toxic concentration, trough level 2 (9 
µg/ml) and 3 (7 µg/ml) was within therapeutic range.  This premature infant was 
admitted to the study with a PNA of 3 days, GA of 33 weeks and his birth weight and 
weight at trial entry was 1160g and 1150g respectively. This premature infant received 
SV. 
Furthermore the premature infant’s albumin level was 23 g/l at trial entry which can also 
contribute to the high trough level 1 observed, because of more unbound vancomycin in 
the serum (Sun et al, 1993, Jackson et al, 1999) 
Due to the correlation found between trough level 1 and PNA in the SV group, one can 
say that with a decrease in PNA there will be an increase in trough level 1. This finding 
is attributed to the premature infant’s immature renal function associated with a small 
PNA (De Hoog et al, 2004). 
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5.5.3.2 Case Study 4 
This premature infant received 16.2mg vancomycin twelve hourly and had a trough level 
1 (19 µg/ml), trough level 2 (14 µg/ml) and 3 (16 µg/ml) above minimum toxic serum 
concentration. 
This male premature infant was admitted to the study with a PNA of 18 days, GA of 28 
weeks, and PMA of 30.5 weeks. His body birth weight and weight at trial entry was 940g 
and 1080g respectively. This premature infant received AV. The dose after trough level 
1 was omitted by the attending physician in order to avoid serious toxicity. 
Possible reasons for this phenomenon are that he had a serum albumin level of 19 g/l 
on trial entry. This may attribute to the high serum trough level concentrations found due 
to more unbound vancomycin (Sun et al, 1993, Jackson et al 1999). 
This premature infant just made the twelve hourly, instead of twenty four hourly dosing 
schedules (Horn et al, 2007) due to PMA of 30.5 weeks. This can also contribute to the 
high trough level 1 concentrations in this premature infant. 
Factors other than demographic (age, weight) and biological (s-Alb, S-creatinine 
concentration, and renal sufficiency) parameters that may influence vancomycin serum 
trough levels (discussed below) could not be excluded. 
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5.5.4 Factors that can influence vancomycin serum trough levels 
Factors that may contribute to vancomycin serum trough levels not being within the 
therapeutic range are: 
5.5.4.1 The timing of trough levels  
5.5.4.2 The presence of impurities e.g. vancomycin crystalline degradation 
product (CDP-1) 
5.5.4.3 The dosing schedule of vancomycin in premature infants 
5.5.4.4 Mode of vancomycin administration 
5.5.4.1 The timing of trough levels 
In this study, international sampling guidelines were followed by collecting the trough 
level thirty minutes prior to vancomycin dose administration (de Hoog et al, (2000); 
McDougal et al, 1995). 
Conflicting evidence exists in literature regarding the sampling time of vancomycin 
serum trough levels. De Hoog et al, (2004) and McDougal et al, (1995) suggests thirty 
minutes prior to the third dose (23h30min), while Rybak et al, (2009) suggests thirty 
minutes prior the fourth dose (35h30min). Time to reach steady state plasma 
concentrations equals five half lives. Vancomycin’s half life in premature infants is 
approximately six hours, and therefore will reach steady state within approximately thirty 
hours (Shargel et al, 2005). In order to prevent the ototoxicity and nephrotoxicity 
associated with vancomycin, it is preferable to measure vancomycin trough levels 
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before steady state is reached. This allows for dose adjustments to be made and 
prevent and limit adverse effects. 
5.5.4.2 The presence of impurities in vancomycin formulations 
Vancomycin breaks down to crystalline degradation product (CDP-1) and factor B 
(active ingredient) when exposed to heat over time (Somerville et al, 1999).  The United 
States Pharmacopoeia (USP) states that any generic formulation of vancomycin may 
not have less that 88% factor B and may not have more than 4% of CDP-1(Somerville 
et al, 1999).  The in vivo and in vitro studies showed that CDP-1 breakdown was 50% at 
sixteen hours in an environment of 20-25ºC. The average NICU temperature is 24-26ºC 
and vancomycin is infused over one hour. This may have an implication on the external 
breakdown of vancomycin prior to its infusion into the neonate. This implication also 
needs further research 
It can be speculated that Sandoz-Vancocin CP® may break down quicker than AV and 
therefore have more than the required 4% CDP-1 present. This finding may lead to 
lower vancomycin serum trough levels than anticipated.   
5.5.4.3 The dosing schedule of vancomycin in premature infants 
In this study a dose of 15mg/kg 12hourly was used for premature infants with a PMA of 
29-35 weeks (Horn et al, 2007) regardless of GA and PNA. 
Many studies have been performed using different dosing strategies of vancomycin in 
premature infants.  Koren & James, (1986) did a study where they divided the 
premature infants into two groups. Group 1 received vancomycin at a dose of 30mg/kg 
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twelve hourly (PNA=0-7days) and eight hourly (PNA>7days). Group 2 received 
vancomycin at 18mg/kg twelve hourly for premature infants with a PMA of 31-36 weeks 
and a body weight of 1200-2000g. They found that for Group 1, 39.6% of trough levels 
were within therapeutic range (60.4% were > 10µg/ml) compared with 75.5% (p=0.002) 
of those in group 2 (22% were > 10µg/ml).  This finding by Koren & James, 1987 
supports the findings in this current study where 36.8% of trough levels 1 were within 
therapeutic range and 57% were > 10µg/ml. Koren & James, 1987 attributed this finding 
to age-dependant maturation of renal function and proposed the dosing schedule on 
both body weight and PMA. 
To further illustrate the difficulties of optimum dosing of vancomycin in premature 
infants, it was also reported by Pacifici & Allegaert (2012) that when vancomycin is 
dosed at 15mg/kg twelve hourly that only 51% of premature infants attained trough 
levels within therapeutic range and that 33% of trough levels were below <5µg/ml. 
Grimsley & Thompson (2012), found that when vancomycin was dosed according to the 
premature infant’s serum creatinine concentration, 72% of first trough levels taken were 
within therapeutic range (5-12µg/ml) 
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5.5.4.4 Intermittent vs. continuous administration of vancomycin 
Vancomycin shows time-dependent killing properties and therefore to maintain the 
vancomycin serum trough concentrations above the given MIC of 2µg/ml, it has been 
suggested that vancomycin can be administered as a continuous infusion (Pacifici et al, 
2012; Rybak et al, 2009). In a study conducted by Pawlotsky et al (1998) they 
administered vancomycin to premature infants with a PMA of 28-51.5 weeks, a loading 
dose of 7mg/kg and followed by a continuous infusion of 10-40mg/kg/24hours according 
PMA. The mean serum trough levels at steady state were 15.4µg/ml.   
Limited literature exist comparing the intermitted vs. continuous infusion administration 
of vancomycin in a premature infant population therefore this method of administration 
was not used in this study. 
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5.6 Treatment outcomes 
It was found that all premature infants that were admitted to this study and that received 
AV was cured and discharged from the NICU’s as per clinical outcomes and physician’s 
discretion. Despite that vancomycin treatment was initiated for suspected MRSA 
infection no premature infant presented with a positive blood culture.  Thus treatment 
was initiated  as per clinical findings and not microbiological confirmation. 
All premature infants that were admitted to the SV group was cured and discharged 
from the NICU’s as per clinical outcomes and the physician’s discretion.  Despite that 
vancomycin treatment was initiated for suspected MRSA infection, no positive blood 
culture was collected.  
The median (range) LOS for the premature infants in AV was 39.5 (26-167) days. The 
LOS of the premature infants that received SV was 70 (13-122) days. The increased 
LOS for the SV group cannot only be attributed to the choice of vancomycin formulation. 
Other factors such as severity of prematurity, respiratory distress syndrome (RDS), 
surgical complications and the presence of a patent ductus ateriosus (PDA) can also 
contribute to the LOS of the premature infants. 
Biological infection markers were used as guide to initiate and to stop vancomycin 
therapy. C-reactive protein (CRP) and procalcitonin (PCT) were both used to evaluate 
the severity of the presumed infection, though literature suggests that a PCT value is 
more accurate for LOS in the premature infant (Chiesa et al, (2011); Nabulsi et al, 
(2012); Vazzalwar et al, (2005). 
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Therapy was discontinued after a negative blood culture and two negative CRP-values 
(Pacifici & Allegaert, (2012). 
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5.7 Were the study objectives achieved? 
Yes the study objectives were achieved. Firstly it was found that there was no statistical 
significant difference between the trough levels 1 of each premature infant in the Aspen-
Vancomycin CP® and those in the Sandoz-Vancocin® group. Despite this finding the 
Sandoz-Vancocin® group had a lower trough level 1 when compared to the Aspen-
Vancomycin CP® group. Thirty six percent of the premature infants in the Aspen-
Vancomycin CP® group had trough level 1 above the minimum toxic concentration 
(>10µg/ml) when compared to the fifteen percent of premature infants of Sandoz-
Vancocin®. 
Secondly it was found that there exists no correlation between the demographic and 
biological parameters and trough level 1 in the AV group. A correlations was found in 
the SV group between trough level 1 and BBW, GA, PMA and PNA. 
Thirdly, it was found that both vancomycin formulations had the same treatment 
outcomes – no therapeutic failure was observed in any premature infant. 
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5.8 Study limitations 
This study was conducted as a randomised prospective study where data collection was 
done according to study protocol and dose scheduling adjustments were done by the 
attending physician, according to the first vancomycin serum trough level.  Therefore 
trough level 2 and 3 were not strictly collected thirty minutes before the sixth and ninth 
dose.   
A major limitation was that the sample size was too small, despite that the statistical 
analysis determined nine premature infants per study arm.  
Vancomycin peak serum concentrations and steady state serum trough concentration 
could not be collected due to NICU protocol (limited blood collection protocol) thus this 
study had not enough data points to determine the pharmacokinetic parameters of 
vancomycin in the premature infant population. 
The concurrent treatment with meropenem made it difficult to determine the 
independent efficacy of vancomycin on treatment outcomes. 
High-performance liquid chromatography (HPLC) was not performed to determine the 
composition of vancomycin crystalline degradation products in the AV and SV group, 
therefore its effect on vancomycin serum trough levels could not be confirmed. 
Vancomycin was not administered as a continues infusion in this study due to limited 
literature available that tested this method in premature infants. 
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6.1 Conclusion 
The main objective of this prospective, double blinded and randomised study was to 
compare the trough levels of Aspen-Vancomycin® and Sandoz Vancocin CP® in a  
premature infant population  
Demographic and biological parameters were assessed and no statistical significant 
difference was found between the two study populations. 
No statistical significant difference were found between trough level 1 in both study 
groups, but the Sandoz Vancocin CP® group had a trend towards lower vancomycin 
serum  trough level 1 concentrations.  
When trough level 1 was compared with demographic and biological parameters it was 
found that the Aspen-Vancomycin® group showed no correlation with any of the 
parameters, this may have been due to outlying trough level 1 values.  In the Sandoz 
Chapter 6 Conclusion and 
Recommendations 
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Vancocin CP® group correlations were found between trough level 1 and GA, PMA, 
PNA. 
It was found that a premature infant’s renal function drives vancomycin trough level 
concentrations and that age or weight are the most relevant determinants  of 
vancomycin clearance. 
 
This study suggests that vancomycin trough levels should be collected 30min prior to 
the third dose to limit toxic serum trough levels and to ensure optimum efficacy. 
This study suggests that Sandoz Vancocin CP® should be used when treating 
premature infants for a suspected MRSA infection.  Sandoz Vancocin CP® offered 
lower vancomycin serum trough levels which ensure a lower risk of toxicity. 
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6.2 Recommendations 
Vancomycin serum peak and steady state trough levels need to be collected in order to 
determine and compare the pharmacokinetic parameters in each study group in a 
premature infant population.  
Therapeutic drug monitoring needs to be applied per individual premature infant in order 
to optimise vancomycin dose adjustments and limit toxicity. 
Studies need to be conducted where a bigger sample size is collected. 
Further studies need to be performed to determine the concentration of CDP-1 by 
means of HPLC method in both Aspen Vancomycin ® and Sandoz-Vancocin CP® and 
its effect on a premature infant population. 
More randomised studies should be performed to determine the efficacy and toxicity of 
continuous and intermitted vancomycin administration in a  premature infant population. 
 
 
. 
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